USCOM LIMITED — Investor Presentation 2021

Aug 2, 2021

“Motivated by Vision Driven by Fundamentals”

USCOM NWR Investor Conference

3[rd] August 2021

Prof. Rob Phillips

ASX: UCM Company Update

WELCOME

==> picture [207 x 198] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

USCOM

Culture

“Motivated by Vision, Driven by Fundamentals”

Mission

Innovative medical science as a foundation for world leading cardiovascular and pulmonary technologies to save lives, and grow Uscom into a world leading medical technology company.

“Science, growth and profit”

Strategy

“More Products, More Distribution, More Sales, and More Revenue”

INFLECTION POINT

“Motivated by Vision, Driven by Fundamentals”

==> picture [76 x 56] intentionally omitted <==

==> picture [75 x 56] intentionally omitted <==

FY2021

FY2022

• Intermittently Profitable

• Multiple New Approvals

• Intermittently Cash +ve

• New Products and IP

• China Profitable

• New distribution

• Europe Profitable

• Expanded regions

• • Cash on Hand • Post-COVID Applications

• • Global Web of • Global Recovery

• Subsidiaries

USCOM

ASX Listed

Global cardiovascular and pulmonary medical technology

Profit and Cash Flow

Intermittent Profit & Cash Flow +ve, Cash in bank and debt free

High Growth and Margins

9 year: total receipts up 535% and 24% CAGR

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Global Vision and Ambitions

Operations: Sydney, Singapore, Beijing, Budapest Offices: Auckland, London, LA

Patented Apex Technologies World leading digital medical technologies, >200 IP submissions

New Products

Expanded global operations for 6 new products in 4 major jurisdictions

“Prepared for the future”

Uscom Devices

USCOM 1A (Heart)

• Advanced haemodynamics

• 2 new models for NMPA – Basic and O2

==> picture [205 x 154] intentionally omitted <==

• Heart failure, Hypertension

BP+ (Vessels)

• BP+ and BP+ Reporter

• Partner service model – cloud

• Hypertension, Vascular Health

SpiroSonic (Lungs)

• SpiroSonic AIR and SpiroReporter

• Patented digital ultrasonic spirometry

• Optimal telehealth application

• Asthma, COPD, OLD and COVID

==> picture [175 x 156] intentionally omitted <==

==> picture [175 x 114] intentionally omitted <==

==> picture [261 x 140] intentionally omitted <==

“Devices addressing diseases responsible for 75% of global mortality”

==> picture [503 x 471] intentionally omitted <==

----- Start of picture text -----

Uscom
UCM Results FY21
6.00
5.46
5.00
4.55 4.60
FY20 FY21 4.28
4.00 3.85
3.48
3.00
2.00
1.00
0.00
Profit Cash Flow -0.34 -0.16 Sales Revenue Cash Receipts
-1.00
-0.87
-1.33
-2.00
$m AUD
----- End of picture text -----

USCOM RESULTS FY21

• Cash receipt $5.46m up 19% from $4.60m

• • Revenue $4.55m up 6% from $4.28m

• Sales revenue $3.85m up 11% from $3.48m

• Total expenses $4.95m down 4% from $5.16m

• Loss reduced to $0.87m, down 54% from $1.34m

• Net cash flow -$0.16m improved 43% from - $0.28m

• Cash on hand $1.71m down from 1.92m

• Debt free

Continued Growth in a Difficult Year

==> picture [476 x 461] intentionally omitted <==

----- Start of picture text -----

Uscom
UCM Total Cash Receipts
$6.00
$5.46
$5.00
$4.60
$4.00
$3.64
$3.50
$2.94
$3.00 $2.86
$2.04
$2.00
$1.38
$0.86 [$1.01 ]
$1.00
$0.00
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
$M AUD
----- End of picture text -----

USCOM RESULTS FY21

• Total cash receipts $5.46M, up 19% from $4.60M

• • 9 year total cash receipts trend growth  24% pa compound annual growth

• 535% total increase

• Uscom China profitable

• • Uscom Europe profitable

Sustained Trend Growth

==> picture [200 x 185] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

Product Sales

USCOM RESULTS FY21

Regional Sales

==> picture [297 x 195] intentionally omitted <==

----- Start of picture text -----

100%
87%
90%
77%
80%
FY20 FY21
70%
60%
50%
40%
30%
19%
20%
12%
10% 4%
1%
0%
USCOM 1A SpiroSonic BP+
----- End of picture text -----

==> picture [367 x 196] intentionally omitted <==

----- Start of picture text -----

80%
71%
70%
64%
FY20 FY21
60%
50%
40%
30% 26%
20%
20%
8%
10% 6%
0% 1% 2% 2%
0%
China/Asia Europe US/Other Australia ROW
----- End of picture text -----

More SpiroSonic and BP+ sales

More European and US sales

USCOM 1A - ★★★★★

• 1500th USCOM 1A Manufactured

• 400 peer reviewed papers

• Life saving, standard of care

• COVID, Sepsis, heart failure, fluid, hypertension, preeclampsia

• Neonates, children and adults

• Installed major hospitals worldwide

“Devices which change medicine are rare; USCOM 1A is one of those!”

COVID, Post-COVID and Uscom

COVID – USCOM 1A

• COVID - Lung virus which attacks cardiovascular system

• COVID patients mostly die from cardiovascular failure

• USCOM 1A best device for rapid CV monitoring and choice of therapy

==> picture [166 x 166] intentionally omitted <==

• USCOM 1 - China National Health and Med Commission for severe COVID treatment

• 50 new China infectious disease centres commissioned with USCOM 1A

Post-COVID Syndrome – SpiroSonic AIR

• ~2B people infected by COVID

• Many develop pulmonary fibrosis during or after COVID

• Need on going home lung monitoring for diagnosis/treatment

• Spirometry market to increase ~160% over 6 years - $2.6B to $6.5B.

• SpiroSonic AIR -most advanced digital ultrasonic spirometry

==> picture [250 x 144] intentionally omitted <==

“Uscom is part of the global COVID recovery story worldwide”

==> picture [198 x 187] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

SpiroSonic AIR and eHEALTH

==> picture [535 x 405] intentionally omitted <==

The SpiroSonic AIR Cycle –a wireless connection of data, information, diagnosis and reports. New digital eHealth model connecting patients to the AIR to the MyAIR app, to the clinician Ideal for home management of asthma, COPD, and COVID and Post-COVID syndrome.

==> picture [198 x 187] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

CHANGING THE COVID SCIENCE

==> picture [600 x 324] intentionally omitted <==

https://www.healtheuropa.eu/post-covid-syndrome-after-the-pandemic-the-pulmonary-consequences/109373/

==> picture [203 x 50] intentionally omitted <==

V ENT IT ES T

V ENT IT ES T-S S o f twa re

==> picture [163 x 191] intentionally omitted <==

==> picture [48 x 77] intentionally omitted <==

==> picture [77 x 63] intentionally omitted <==

==> picture [406 x 245] intentionally omitted <==

For testing, archiving, analysis, display and reporting of ventilator performance

USCOM PRODUCTS

==> picture [858 x 461] intentionally omitted <==

----- Start of picture text -----

U S C O M 1 A
data data
USCOM 1A software SpiroReporter
Uscom Advanced Haemodynamic APP MyAIR APP
Blue Sky
Uscom eHealth Ecosystem
data data
AI, Meta Data,
Licensing, Cloud services, Pay
BP+ Reporter VENTITEST-S
per use, Rental, Subscription,
Partnerships, Data
licensing/sale/research, Third
party rentals for access to the
“Ecosystem”
----- End of picture text -----

==> picture [200 x 187] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

EXPANDING WEB OF DISTRIBUTION

• London • Beijing • Budapest 35 People • LA 4 Markets China (1.4b) • Singapore SE Asia (1b) Europe (0.75b) US (0.33b) • Sydney • Auckland Headquarters Australia (0.025b)

Massive Markets, Massive Opportunity

CHINA RECOGNITION

==> picture [353 x 238] intentionally omitted <==

==> picture [336 x 238] intentionally omitted <==

Uscom China Listed as China National High Technology Enterprise by PRC Ministry of Science and Technology

Uscom China ranked AAA Credit Enterprise by China Credit Enterprise Publicity Network

“Building a Global Business”

==> picture [42 x 13] intentionally omitted <==

----- Start of picture text -----

China
----- End of picture text -----

GLOBAL REGULATORY

==> picture [903 x 363] intentionally omitted <==

----- Start of picture text -----

SE Asia
TICKING THE BOXES
Europe
Regions
Approvals
US
China SE Asia Euro US Russia ROW
Russia
U S C O M ✓
1 A
2021
✓ ✓ ✓ 2022
✓ ✓ ✓
Pending
✓ ✓ ✓
✓ ✓ ✓
----- End of picture text -----

✓ New Approvals

7 New Approvals

12 Product Regions for sale in FY22, up from 5 (up 140%)

==> picture [46 x 55] intentionally omitted <==

==> picture [199 x 192] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

STRATEGY FY22

7 new approvals for USCOM 1A, BP+, SpiroSonic

Up 140%!

“more products, more distributors, more sales and more revenue” FY22

==> picture [815 x 531] intentionally omitted <==

----- Start of picture text -----

STRATEGY FY22
Uscom
Uscom Revenue Model
More
VENTITEST
 Markets BP+
SpiroSonic
 Products
USCOM 1A
 Distributors R&D
 Sales
 Revenue
 Profit
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
“more products, more distributors, more sales and more revenue”
FY22
$m AUD
----- End of picture text -----*

REGIONAL STRATEGY FY22

Uscom China

==> picture [66 x 7] intentionally omitted <==

01

More, bigger and better distribution, prepare BP+ and SpiroSonic distribution, domestic manufacture

Uscom Europe

==> picture [128 x 7] intentionally omitted <==

02

Growing manufacturing, distribution and sales for USCOM 1A, BP+ and SpiroSonic

Uscom SE Asia

FY22

==> picture [73 x 7] intentionally omitted <==

==> picture [82 x 7] intentionally omitted <==

03

04

Singapore based regional distribution and regulatory hub for USCOM 1A, SpiroSonic and BP+

Uscom US

Activate new distribution model to meet post pandemic demand and prepare for SpiroSonic and BP+

INVESTMENT

“Hunt for stock market treasures: Outperforming value plays with growth potential” CNBC Trading Nation - 26[th] December 2020 Attractive valuation (low multiple) High potential for earnings growth Quarterly outperformance High value sector

“Motivated by Vision, Driven by Fundamentals” FY22

USCOM

Culture

“Motivated by Vision, Driven by Fundamentals”

==> picture [197 x 195] intentionally omitted <==

----- Start of picture text -----

Uscom
----- End of picture text -----

Mission

Innovative medical science as a foundation for world leading cardiovascular and pulmonary technologies to save lives, and grow Uscom into a world leading medical technology company.

“Science, growth and profit”

Strategy

“More Products, More Distribution, More Sales, and More Revenue” FY22

“Motivated by Vision Driven by Fundamentals”

USCOM NWR Investor Conference

3[rd] August 2021

Prof. Rob Phillips

ASX: UCM Company Update

WELCOME

Corporate Responsibility

==> picture [715 x 464] intentionally omitted <==

----- Start of picture text -----

UCM – Investor Presentation April 2020
----- End of picture text -----

Uscom supports the Australian Wildlife Conservancy.

in the last 15 years Australia's threatened species list has increased by 36%.

87% of our mammal species, 93% of reptiles, 94% of frogs and 45% of our bird species are found only in Australia.

AWC is committed to reversing Australia’s record as the world’s mammalian extinction capital.